Phase III Randomized Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
This randomized phase III trial studies how well giving hormone therapy together with or without everolimus work in treating patients with breast cancer.
Description
The purpose of this study is to compare whether the addition of one year of everolimus (10 mg daily) to standard adjuvant endocrine therapy improves invasive disease-free survival (IDFS) in patients with high-risk, hormone-receptor (HR)-positive, and human epidermal growth factor receptor (HER)2-negative breast cancer.
Details
| Condition | Breast Cancer |
|---|---|
| Age | 18years - 100years |
| Clinical Study Identifier | TX4054 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.